Daily ReportOct 29, 2026
Sepsis, October 29 edition
We read 44 papers and selected 3.
Summary
Today's most impactful sepsis research advances three complementary areas: immune phenotyping, clinically reproducible sepsis subtyping, and direct measurement of inflammasome activation. A multicenter transplant cohort identified a distinct immunometabolic sepsis phenotype associated with substantially better survival, while a large international analysis validated consensus clinical profiles across diverse critical-care cohorts. A prospective pilot study further showed that cell-resolved NLRP3 inflammasome activity has a nonlinear association with mortality, supporting biologically informed risk stratification.
Research Themes
- Immune and immunometabolic phenotyping of sepsis
- Reproducible clinical subtyping across international cohorts
- Direct measurement of inflammasome activity and nonlinear prognosis
Selected Articles
1. Immunological signatures of sepsis in abdominal solid organ transplant recipients: A multilayer and multicentric prospective cohort study.
In a post hoc analysis of a prospective multicenter cohort, abdominal solid organ transplant recipients with sepsis had higher 30-day survival than non-transplant patients (84% versus 66%; adjusted hazard ratio 0.49). They showed lower IL-6 and TNF-α, higher IL-18, relatively preserved monocytic HLA-DR expression, and distinct innate immune, complement, lipid-metabolic, and cellular immunometabolic signatures. The findings suggest that chronic immunosuppression may reshape rather than simply suppress the septic host response.
Impact: This study challenges the assumption that chronic immunosuppression uniformly worsens sepsis outcomes and links survival differences to measurable immune and immunometabolic mechanisms. Its multilayer design provides a strong framework for biologically informed phenotyping of immunocompromised patients.
Clinical Implications: Transplant status should not be interpreted as an automatic marker of poor prognosis in sepsis. Immune profiling, particularly monocytic HLA-DR, cytokine patterns, and immunometabolic markers, may eventually support individualized monitoring and treatment, although these markers are not yet validated for routine therapeutic decisions.
Key Findings
- Thirty-day survival was 84% in abdominal solid organ transplant recipients versus 66% in non-transplant patients; adjusted hazard ratio was 0.49.
- Transplant recipients had lower IL-6 and TNF-α, higher IL-18, and relatively preserved monocytic HLA-DR expression.
- Proteomic and intracellular analyses identified distinct innate immune, complement, lipid-metabolic, GLUT1, and TFAM/TFB2M-associated signatures.
Methodological Strengths
- Prospective multicenter cohort framework with multivariable survival analysis
- Multilayer immune assessment integrating cytokines, flow cytometry, proteomics, and intracellular signaling
Limitations
- The transplant analysis was post hoc and observational, so residual confounding and selection bias cannot be excluded.
- Immune and immunometabolic markers were not prospectively tested to guide treatment allocation.
Future Directions: Prospective studies should validate whether the identified immune signatures predict treatment response and whether transplant-specific phenotypes can guide immunomodulatory or organ-support strategies.
BACKGROUND: Sepsis is defined as life-threatening organ dysfunction resulting from a dysregulated host response to infection. Patients with prior abdominal solid organ transplantation (SOT) are highly susceptible to infection due to chronic immunosuppression, yet exhibit improved survival once sepsis occurs. The underlying mechanisms remain poorly understood. METHODS: We conducted a post hoc analysis within a prospective multicenter cohort of septic patients (SepsisDataNet.NRW; n = 538). Clinical outcomes were assessed using Kaplan-Meier analysis and multivariable Cox regression. Immune profiling included serum cytokines, flow cytometric immunophenotyping, plasma proteomics, and intracellular signaling using proximity ligation assays (PLA) in peripheral blood mononuclear cells (PBMCs).
2. Consensus-derived clinical sepsis profiles and mortality across six international cohorts.
Using 62,458 adults from six critical-care databases in four countries, investigators derived three clinically interpretable sepsis profiles from 24 routinely available variables and assigned them to five external cohorts. Profile 1, characterized by greater multiorgan dysfunction, consistently had the highest mortality, while Profile 3 had lower 1-year mortality than Profile 1 after adjustment for age and SOFA score. The findings support reproducible clinical phenotyping for risk stratification and phenotype-informed trials.
Impact: This is a large-scale, internationally replicated evaluation of sepsis heterogeneity using variables available in routine care. It moves clinical phenotyping closer to transportable implementation and provides a practical framework for future phenotype-enriched trials.
Clinical Implications: The profiles may complement SOFA and other severity scores for prognostic communication, cohort enrichment, and trial design. They should not yet be used as stand-alone treatment algorithms because treatment-outcome associations were exploratory.
Key Findings
- Three profiles were derived from 24 routinely available clinical variables in 28,733 MIMIC-IV patients and assigned to five external cohorts.
- Profile 1 had the highest mortality and was characterized by greater multiorgan dysfunction; discovery-cohort mortality was 30.3%.
- After age and SOFA adjustment, Profile 3 had lower 1-year mortality than Profile 1, with a hazard ratio of 0.62.
Methodological Strengths
- Very large sample drawn from six international critical-care cohorts
- External validation using fixed discovery-cohort templates and multiple clustering algorithms
Limitations
- The study used retrospective critical-care databases with potential differences in coding, case mix, and missing data across countries.
- Treatment-outcome associations were exploratory and do not establish phenotype-specific treatment effects.
Future Directions: Future work should prospectively validate real-time assignment of the profiles, assess calibration in non-ICU settings, and test whether phenotype-guided treatment or trial enrollment improves outcomes.
BACKGROUND: Clinical phenotyping may help characterize sepsis heterogeneity, but the applicability of derived profiles across healthcare settings remains uncertain. We evaluated consensus-derived clinical profiles and their associations with mortality across six international cohorts. METHODS: We analyzed 62,458 adults from six critical care databases in four countries. In the MIMIC-IV discovery cohort (n = 28,733), six clustering algorithms were applied to 24 routinely available clinical variables to derive consensus profiles. The profiles were assigned in five external cohorts using fixed discovery-cohort templates.
3. Quantification of NLRP3-caspase-1 complex assembly reveals a non-linear association with 30-day mortality in sepsis: a proof-of-concept pilot study.
This prospective multicenter proof-of-concept study applied a validated proximity ligation assay to directly quantify NLRP3-caspase-1 complex assembly in peripheral blood mononuclear cells from 78 patients with sepsis. Both low and high inflammasome activity were associated with increased 30-day mortality, whereas intermediate activity was associated with the most favorable outcomes. The nonlinear relationship was confirmed with restricted cubic splines, suggesting that both inadequate and excessive inflammasome activation may be harmful.
Impact: The study introduces a cell-resolved, direct assay of inflammasome assembly rather than relying on nonspecific downstream cytokines. Its nonlinear result challenges the assumption that more inflammation is uniformly worse and supports a more nuanced model of immune-state heterogeneity in sepsis.
Clinical Implications: Direct inflammasome profiling could eventually help identify biologically distinct sepsis states and guide immunomodulatory trials. The assay is not ready for routine risk stratification because the cohort was small and independent validation is lacking.
Key Findings
- A proximity ligation assay enabled direct, cell-resolved quantification of NLRP3-caspase-1 complex formation in septic patients.
- Both low and high inflammasome activity were associated with increased 30-day mortality; adjusted hazard ratios were 7.88 and 4.35, respectively.
- Restricted cubic spline analysis confirmed a significant nonlinear association between inflammasome activity and mortality.
Methodological Strengths
- Prospective multicenter clinical pilot with prior assay validation in THP-1-derived macrophages
- Direct single-cell in situ measurement rather than indirect cytokine surrogates, with nonlinear statistical modeling
Limitations
- The sample size was small, with 78 patients divided into three activity groups.
- The observational design cannot establish whether inflammasome activity is causally related to mortality, and external validation is required.
Future Directions: Larger prospective cohorts should validate assay reproducibility, define clinically actionable thresholds, and test whether inflammasome-state-guided immunomodulation improves outcomes without worsening infection control.
BACKGROUND: Direct, cell-resolved quantification of NLRP3 inflammasome activation in clinical patients has not been feasible. Previous studies have relied on indirect surrogates such as downstream cytokines, which are influenced by inflammasome-independent pathways and systemic clearance kinetics, potentially explaining the inconsistent prognostic findings reported in the literature. We applied a proximity ligation assay (PLA) to directly visualise NLRP3-caspase-1 complex formation in peripheral blood mononuclear cells of septic patients, providing a cell-specific, in situ readout of inflammasome assembly at the single-cell level.